Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Arizona State Retirement System

Arizona State Retirement System trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,390 shares of the biopharmaceutical company’s stock after selling 2,122 shares during the quarter. Arizona State Retirement System’s holdings in Alnylam Pharmaceuticals were worth $14,470,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Mediolanum International Funds Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $11,389,000. Rakuten Investment Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $14,205,000. Generali Asset Management SPA SGR increased its stake in Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 3,184 shares during the period. Cerity Partners LLC increased its stake in Alnylam Pharmaceuticals by 171.2% during the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company’s stock worth $12,507,000 after buying an additional 17,316 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $5,790,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Needham & Company LLC cut their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Oppenheimer initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $472.78.

Alnylam Pharmaceuticals Stock Down 2.6%

ALNY stock opened at $305.54 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $240.00 and a one year high of $495.55. The stock has a market capitalization of $40.77 billion, a PE ratio of 178.68 and a beta of 0.39. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The company has a fifty day moving average of $322.07 and a 200-day moving average of $381.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.65) EPS. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.75 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider directly owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the sale, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 38,656 shares of company stock valued at $12,370,696. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.